GBS vaccines have been investigated as a tool for reducing maternal colonization and preventing transmission to neonates; however, no licensed vaccine is available currently.  Phase I and II clinical trials among healthy, non-pregnant adults of monovalent polysaccharide-protein conjugate vaccines of GBS disease-associated types have shown these vaccines to be well tolerated and immunogenic.  A recent, double-blind randomized trial of a conjugate vaccine against GBS serotype III among non-pregnant women of reproductive age found a significant delay in acquisition of colonization with the vaccine-serotype among vaccine recipients.
Group B streptococcal infection future or investigational therapies
Group B streptococcal infection primary prevention
Group B streptococcal infection secondary prevention
Listeriosis future or investigational therapies
Influenza future or investigational therapies
Group B streptococcal infection medical therapy
Diphtheria primary prevention
Diphtheria medical therapy